L245-0154 Screening compound: N-[3-(3-methylpiperidin-1-yl)propyl]-1-{5-oxo-5H,6H,7H,8H,9H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl}piperidine-4-carboxamide

L245-0154 Screening compound: N-[3-(3-methylpiperidin-1-yl)propyl]-1-{5-oxo-5H,6H,7H,8H,9H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl}piperidine-4-carboxamide
L245-0154 Screening compound: N-[3-(3-methylpiperidin-1-yl)propyl]-1-{5-oxo-5H,6H,7H,8H,9H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl}piperidine-4-carboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L245-0154
N-[3-(3-methylpiperidin-1-yl)propyl]-1-{5-oxo-5H,6H,7H,8H,9H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl}piperidine-4-carboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L245-0154

Molecular Formula

C24H36N6O2S (C24 H36 N6 O2 S)

Compound Name

N-[3-(3-methylpiperidin-1-yl)propyl]-1-{5-oxo-5H,6H,7H,8H,9H-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-yl}piperidine-4-carboxamide

IUPAC name

N-[3-(3-methylpiperidin-1-yl)propyl]-1-{5-oxo-5H6H7H8H9H-[134]thiadiazolo[23-b]quinazolin-2-yl}piperidine-4-carboxamide

SMILES

CC1CN(CCCNC(C(CC2)CCN2C(SC2=NC3=C4CCCC3)=NN2C4=O)=O)CCC1

InChI

InChI=1S/C24H36N6O2S/c1-17-6-4-12-28(16-17)13-5-11-25-21(31)18-9-14-29(15-10-18)24-27-30-22(32)19-7-2-3-8-20(19)26-23(30)33-24/h17-18H,2-16H2,1H3,(H,25,31)/t17-/m0/s1

InChI Key

DOLPKILLNVUBTD-KRWDZBQOSA-N

MDL Number (MFCD)

MFCD15120889

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

472.66

Hydrogen Bond Acceptors Count

8.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

7.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

2.263

Distribution Coefficient, logD

-0.366

Water Solubility, LogSw

-2.46

Polar Surface Area

68.979

Acid Dissociation Constant (pKa)

15.07

Base Dissociation Constant (pKb)

10.03

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

75.00

L245-0154 in Drug Discovery

Included in Screening Libraries

Cysteine Proteases Inhibitors Library (7839 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

Akt-Targeted Library (14764 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Hemic and lymphatic
  • Cardiovascular
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
Targets:
  • Proteases
  • Kinases

References: we are preparing a list of scientific research reports with L245-0154 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L245-0154?
Check Price and Availability of L245-0154, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L245-0154 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L245-0154
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L245-0154
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L245-0154 available by request